Pfizer, Inc. · NYSE:PFE
Pfizer — UBS Life Sciences Conference 2007
20 slides from Pfizer's conference presentation, Sep 26, 2007
Slide 1: Continuing Momentum in Advancing Our Pipeline
Continuing Momentum in Advancing Our Pipeline UBS Life Sciences Conference Martin Mackay Vice President, PGRD Senior Vice President, WW Development September 26, 2007
Slide 2: Cautionary Language
Cautionary Language The discussions at this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in our 2006 Annual Report on Form 10-K and i
Slide 3: Rich in Substrate
Rich in Substrate 85 85 distinct distinct new new molecular molecular entities entities in in our our pipeline pipeline 14 14 biological biological programs programs in in development development Additional Additional 72 72 projects projects to to evaluate evaluate new new indications in
Slide 4: Pfizer R&D Pipeline
Pfizer R&D Pipeline (updated July 31, 2007) 27 Programs Advanced* Discovery Projects +7 +14 +3 +1 +2 Phase 1 Phase 2 Phase 3 In Reg. 38 47 11 3 Approved Fesoterodine (EU) Lyrica -4 -1 (fibromyalgia USA) -8 13 Programs Discontinued * Pipeline represents progress of R&D programs since 12/06, across 11
Slide 5: Phase 3 Programs: Building Momentum in Oncology
Phase 3 Programs Building Momentum in Oncology Sutent NSCLC, Breast, Colorectal Axitinib Thyroid and Pancreatic Cancer CP-675206 Melanoma Phase 3 11 Valid as of September 26, 2007 5
Slide 6: US First-Line Total RCC Patients
US US First-Line First-Line Total Total RCC RCC Patients Patients (August (August 2007: 2007: N=155) N=155) U.S. U.S. and and ex-U.S. ex-U.S. approvals approvals for for first-line first-line advanced advanced RCC, RCC, 60% SUTENT 59% including including mRCC mRCC U.S. U.S. and and ex-U.S. e
Slide 7: Axitinib
Axitinib VEGFR Tyrosine Kinase Inhibitor Oral, small-molecule angiogenesis inhibitor of all currently known VEGF receptors (1, 2, and 3) Phase 3 trials ongoing in refractory thyroid cancer and pancreatic cancer Multiple Phase 2 studies ongoing Valid as of September 26, 2007 7
Slide 8: Axitinib: Refractory Thyroid Cancer
Axitinib Refractory Thyroid Cancer Phase 2 Study in Patients with Advanced Refractory Thyroid Cancer 60 Patients Enrolled Primary Endpoint: Response Rate by RECIST No. % Partial Response 13 22% Stable Disease* 30 50% Any Tumor Shrinkage 28 47% No Response 17 28% Progression 7 12% Indeterminate/Unkno
Slide 9: CP-675206 CTLA4 Inhibitor
CP-675206 CTLA4 Inhibitor Fully Fully human human monoclonal monoclonal antibody antibody Administered Administered byby IV IV injection injection every every 33 months months Blocks Blocks CTLA4 CTLA4 receptor receptor toto release release “brake,” “brake,” allow allow proliferation pro
Slide 10: Refractory Metastatic Adenocarcinoma of the Colon or Rectum
CP-675206 Refractory Metastatic Adenocarcinoma of the Colon or Rectum Key findings In pretreated patients with colorectal cancer and good performance status, CP-675206 was tolerable An objective response was seen in one patient Based on its mechanism of action and manageable toxicity
Slide 11: A Breakthrough in HIV Therapy
A Breakthrough in HIV Therapy FDA approval in treatment-experienced patients with CCR5-tropic HIV – August 2007 European approval of Celsentri this week MOTIVATE 1 48-week analysis presented at ICAAC last week Three times as many patients receiving SELZENTRY achieved undetectable HIV
Slide 12: Exciting Phase 2 Candidates
Exciting Phase 2 Candidates CP-690550 RA and Transplant PD-332334 Generalized Anxiety Disorder Phase 2 47 Valid as of September 26, 2007 12
Slide 13: CP-690550 Shows Potential across many Diseases
CP-690550 Shows Potential across many Diseases Human genetics implicated JAK 3 as target for immune-system disorders CP-690550 shown to be effective in organ transplant Rheumatoid arthritis is an autoimmune disorder hence our desire to test in this indication Valid as of September 26, 20
Slide 14: Promising Results in RA
CP-690550 Promising Results in RA 100 80 60 40 20 0 0 2 4 6 Weeks 5 mg 15 mg 30 mg Placebo Patients With ACR20 Response (%) Valid as of September 26, 2007 14
Slide 15: PD-332334 Alpha-2-Delta
PD-332334 Alpha-2-Delta Well tolerated Phase 3 planning underway Valid as of September 26, 2007 15
Slide 16: Impressive Results in Anxiety
PD-332334 Impressive Results in Anxiety 50% 48% 38% Responder Rates (%) 40% 31% Placebo 29% 30% 26% PD-332334 250mg BID XanaxXR 1mg BID 20% 13% 10% 0% Week 1 Week 4 % % of of Patients Patients Greater Greater Than Than or or Equal Equal to to 50% 50% Reduction Reduction HAM-A HAM-A Valid as of Septe
Slide 17: Intensified Focus on Biotherapeutics and Vaccines
Intensified Focus on Biotherapeutics and Vaccines Biotherapeutics Goal to increase to 20% the number of biologics in our internal portfolio, leading to one product launch per year within 10 years Monoclonal antibodies have a proven favorable survival profile Opens up new target space and
Slide 18: Expanding Science Outside our Walls
Expanding Science Outside our Walls Pfizer External Research Network – The Pfizer Incubator To gain rapid, broader access to science underlying disease and to enabling technologies Foundation for National Institutes of Health GAIN (Genetic Association Information Network) program
Slide 19: Strong and Growing Portfolio
Strong and Growing Portfolio Driving growth in our new and in-line products Maximizing value Valid as of September 26, 2007 19
Slide 20: Continuing Momentum in Advancing Our Pipeline
Continuing Momentum in Advancing Our Pipeline UBS Life Sciences Conference Martin Mackay Vice President, PGRD Senior Vice President, WW Development September 26, 2007 Valid as of September 26, 2007